To compare the cost-effectiveness of interferon-alpha with that of hydroxyurea as initial therapy for patients with chronic myelogenous leukemia (CML) in the chronic phase.
A decision analysis and Markov model that described the natural history of the therapeutic process.
The Markov model contained two treatment arms (interferon-alpha and hydroxyurea) and eight states of health (complete hematologic remission with cytogenetic response, complete hematologic remission without cytogenetic response, partial hematologic remission, chronic phase without hematologic remission, accelerated phase, blast crisis, bone marrow transplantation, and death).
Probabilities, costs, and utilities were obtained from published clinical studies and clinical investigators.
Quality-adjusted years of life saved and costs and qualities discounted at 5% per year.
University medical centers in North America and Europe.
Meta-analysis of results from patients studied in clinical trials.
The model's predictions of median survival (69 months with interferon-alpha therapy and 58 months with hydroxyurea therapy) were derived from data in the recent literature.
In patients 50 years of age, interferon-alpha improved life expectancy over hydroxyurea by approximately 18 months. (...)
Mots-clés Pascal : Leucémie myéloïde, Homme, Traitement, Chimiothérapie, Etude comparative, Interféron alpha, Immunothérapie, Hydroxycarbamide, Anticancéreux, Analyse coût efficacité, Economie santé, Analyse décision, Modèle Markov, Chronique, Hémopathie maligne, Myéloprolifératif syndrome, Cytokine
Mots-clés Pascal anglais : Chronic myelocytic leukemia, Human, Treatment, Chemotherapy, Comparative study, Alpha interferon, Immunotherapy, Antineoplastic agent, Cost efficiency analysis, Health economy, Decision analysis, Markov model, Chronic, Malignant hemopathy, Myeloproliferative syndrome, Cytokine
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0464354
Code Inist : 002B02R03. Création : 10/04/1997.